Nav: Home

NIH-funded Antibacterial Resistance Leadership Group details progress, challenges

March 09, 2017

In June 2013, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), provided $2 million in funding to establish an Antibacterial Resistance Leadership Group (ARLG) to develop, prioritize and implement a clinical research agenda to address the growing public health threat of antibiotic resistance. A new series of articles appearing in the March 15th issue of the journal Clinical Infectious Diseases details the group's progress and outlines its ongoing and future efforts.

Antimicrobial-resistant bacteria cause more than 2 million infections and about 23,000 deaths each year in the United States, resulting in approximately $20 billion in excess medical spending and $35 billion in lost productivity. NIAID created the ARLG to address key clinical research questions of the antibacterial resistance problem in a well-coordinated manner.

Since its inception, the group has focused on four key areas
  • Infections caused by gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae and other carbapenem-resistant Enterobacteriaceae (CRE)

  • Infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci
  • Antimicrobial stewardship and infection prevention
  • Diagnostics
To date, the ARLG has reviewed more than 70 study proposals and initiated more than 30 clinical studies to address these issues. Many of these studies have involved innovative approaches, including adaptive designs to optimize enrollment in therapeutic trials, master protocols to simultaneously evaluate multiple diagnostic tests using specimens from a single patient and novel trial designs that increase clinical trial efficiencies and enable use of improved clinical trial designs.

One of the group's key accomplishments is the launch of the CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) study, a prospective multicenter, cohort study designed to characterize the risk factors for and outcomes of infections caused by CRE and to identify barriers to enrollment that will inform future clinical trials. The study has enrolled more than 1,000 patients with CRE infection or bacterial colonization in the United States and South America.

There are encouraging signs in the fight against antibacterial resistance, the authors write, but the regulatory and approval processes for antibiotics and diagnostics need to allow more innovative clinical trial designs that could improve efficiencies, enrollment and overall study quality. Additionally, there must be an ongoing federal financial commitment to incentivize drug discovery and development, the authors note.
-end-
ARTICLE: The ARLG supplement of articles appears in Clinical Infectious Diseases, Vol. 64.

NIAID Director Anthony S. Fauci, M.D., and Dennis Dixon, M.D., chief of the Bacteriology and Mycology Branch in NIAID's Division of Microbiology and Infectious Diseases, are available to comment on the article series.

CONTACT: To schedule interviews, please contact the NIAID News and Science Writing Branch, (301) 402-1663, niaidnews@niaid.nih.gov.


NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH...Turning Discovery Into Health®

NIH/National Institute of Allergy and Infectious Diseases

Related Antibiotic Resistance Articles:

Antibiotic-resistance in Tanzania is an environmental problem
WSU study finds that environmental transmission rather than antibiotic use explains the presence of antibiotic-resistant bacteria in people, domestic animals and wildlife.
Stressed-out dust is sharing antibiotic resistance genes
A new Northwestern University study is the first to find that bacteria living in household dust can spread antibiotic resistance genes.
Cause of antibiotic resistance identified
Bacteria can change form in human body, hiding the cell wall inside themselves to avoid detection.
The solution to antibiotic resistance could be in your kitchen sponge
Researchers from the New York Institute of Technology (NYIT) have discovered bacteriophages, viruses that infect bacteria, living in their kitchen sponges.
Antibiotic resistance in spore-forming probiotic bacteria
New research has found that six probiotic Bacillus strains are resistant to several antibiotics.
How bacteria acquire antibiotic resistance in the presence of antibiotics
A new study's disconcerting findings reveal how antibiotic resistance is able to spread between bacteria cells despite the presence of antibiotics that should prevent them from growing.
Five rules to tackle antibiotic resistance
Current efforts to tackle antibiotic resistance are 'not nearly radical enough,' a leading scientist says.
Breaking open the gates of antibiotic resistance
Creating a defect in tRNA molecules could weaken bacteria's two-pronged defense and help make faster-acting antibiotics
Wastewater reveals the levels of antibiotic resistance in a region
A comparison of seven European countries shows that the amount of antibiotic resistance genes in wastewater reflects the prevalence of clinical antibiotic resistance in the region.
Bacteria 'trap' could help slow down antibiotic resistance
Scientists have developed a new and faster test for identifying how single bacteria react to antibiotics, which could help in the fight against antimicrobial resistance.
More Antibiotic Resistance News and Antibiotic Resistance Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.